Magnetic Resonance Imaging as an Early Indicator of Clinical Outcome in Patients With Metastatic Colorectal Carcinoma Treated With Cetuximab or Panitumumab

Abstract

Early detection of tumor response by week-2 MRI without contrast medium is associated with a prediction of clinical outcome in patients with metastatic colorectal carcinoma treated with cetuximab or panitumumab.

Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC)

“…An early assessment of tumour shrinkage may provide guidance for treatment at the time of first restaging [22][23][24][25]. Indeed, early tumour shrinkage (ETS) has recently come to the attention of clinicians as a favourable prognostic marker for both PFS and OS in patients with mCRC receiving first-line treatment [24][25][26][27].…”

Impact of early tumor shrinkage on clinical outcome in wild‐type‐KRAS colorectal liver metastases treated with cetuximab

“…Due to the emergence of more accurate imaging techniques, several scholars recently suggested that early tumor shrinkage (ETS) could predict long‐term survival in response to targeted‐chemotherapy combination treatment (Table ). Piessevaux et al .…”

A complete response to mFOLFOX6 and panitumumab chemotherapy in advanced stage rectal adenocarcinoma: a case report

“…However, a pilot study demonstrated clear downstaging of primary colon cancer with only three cycles of NAC [22]. Another report showed that detection, by week 2 magnetic resonance imaging, of tumor shrinkage >10% in response to therapy with Cmab or Pmab for metastatic colorectal cancer represents an early indicator of clinical outcome because it is predictive of the prolongation of progression-free survival and overall survival [4]. We thought that if NAC was not effective, the patient would not be able to receive curative surgery because of disease progression.…”

“…reported that neoadjuvant CRT may adversely affect anorectal function [5]. It has also been reported that Cmab and Pmab-containing chemotherapy enables early tumor shrinkage [4]. For these reasons, neoadjuvant chemotherapy (NAC) with mFOLFOX6 and Pmab was performed every 2 weeks with the patient’s written, informed consent.…”

“…However, it was reported that postoperative anal function was decreased when the effect of preoperative CRT was strong in patients treated with intersphincteric resection (ISR) [3]. Use of panitumumab (Pmab) and cetuximab (Cmab), anti-endothelial growth factor receptor (EGFR) antibodies, has resulted in earlier tumor shrinkage for K-ras wild type metastatic colorectal cancer [4]. The case of a 53-year-old man with stage III low rectal cancer who had a complete response to neoadjuvant oxaliplatin, 5-fluorouracil (5-FU) and l-folinic acid (mFOLFOX6) and Pmab chemotherapy without concurrent radiotherapy is reported.…”